Recently, TGM2 was found to correlate with chemoresistance to cisplatin through the activation of mitogen-activated protein kinase and AKT serine/threonine kinase pathways.[30] Furthermore, TGM2 could also serve as a target for angiogenesis, cell cycle arrest, and early apoptosis in other cancers.[31–34] Meanwhile, we turned our attention to the IL4R, which is involved in anti-tumorigenesis. The gene discussed is MARK2; the disease is cancer.